Wedbush Reiterates Outperform on Fennec Pharmaceuticals, Maintains $13 Price Target
Benzinga Newsdesk 6 months ago
NewsPrice TargetReiterationAnalyst Ratings
Wedbush analyst David Nierengarten reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and maintains $13 price target.
Wedbush analyst David Nierengarten reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and maintains $13 price target.